We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

76 hedge funds and large institutions have $29.3M invested in Outlook Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

16% more capital invested

Capital invested by funds: $25.3M → $29.3M (+$4.01M)

1% more funds holding

Funds holding: 75 → 76 (+1)

0.02% less ownership

Funds ownership: 0.55% → 0.53% (-0.02%)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
26
Reduced
18
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$188K
2
AA
Ancora Advisors
Ohio
+$101K
3
State Street
State Street
Massachusetts
+$69.4K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.7K
5
Squarepoint
Squarepoint
New York
+$37.3K

Top Sellers

Rank Fund Capital Flow
1
VF
Vista Finance
Missouri
-$724K
2
Renaissance Technologies
Renaissance Technologies
New York
-$187K
3
Millennium Management
Millennium Management
New York
-$183K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$179K
5
BlackRock
BlackRock
New York
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
51
Commonwealth Equity Services
Massachusetts
$20K – – –
KW
52
KWB Wealth
California
$20K – – –
Victory Capital Management
53
Victory Capital Management
Texas
$18K -$4.53K -195 -20%
Osaic Holdings
54
Osaic Holdings
Arizona
$16K -$884 -38 -5%
ProShare Advisors
55
ProShare Advisors
Maryland
$16K -$279 -12 -2%
Legal & General Group
56
Legal & General Group
United Kingdom
$15K – – –
MFGP
57
Marshall Financial Group (Pennsylvania)
Pennsylvania
$14K – – –
Jane Street
58
Jane Street
New York
$13K +$12.3K +528 New
D.E. Shaw & Co
59
D.E. Shaw & Co
New York
$13K +$12.3K +530 New
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$12.3K -$18.3K -789 -61%
CAPTRUST Financial Advisors
61
CAPTRUST Financial Advisors
North Carolina
$12K – – –
CB
62
CNB Bank
Pennsylvania
$12K – – –
CCM
63
Crew Capital Management
Ohio
$12K – – –
GC
64
Grimes & Company
Massachusetts
$12K – – –
IAMOG
65
Investors Asset Management of Georgia
Georgia
$12K – – –
TCA
66
Transcend Capital Advisors
New Jersey
$12K – – –
FMI
67
F/M Investments
District of Columbia
$12K +$11.6K +500 New
AIP
68
Ameritas Investment Partners
Nebraska
$8K – – –
Barclays
69
Barclays
United Kingdom
$6K -$1.07K -46 -15%
APA
70
American Portfolios Advisors
New York
$4.88K – – –
Citigroup
71
Citigroup
New York
$2K -$6.93K -298 -77%
PWMG
72
Prestige Wealth Management Group
New Jersey
$2K – – –
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$2K +$884 +38 +112%
HI
74
Harbour Investments
Wisconsin
$1K – – –
CS
75
Credit Suisse
Switzerland
$1K +$767 +33 +3,300%
1 2
3
4

OTLK Hedge Fund Activity: Q3 2022 in Review

76 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2022, worth a combined $29.3M — up 16% from $25.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OTLK positions and 5 closed out — a net gain of 2 holders — while 26 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $188K. The largest seller was Vista Finance, cutting an estimated $724K.

  • 76 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2022, up from 75 in Q2 2022.
  • Funds reported $29.3M of Outlook Therapeutics stock for Q3 2022, up 16% quarter-over-quarter.
  • 7 funds opened new Outlook Therapeutics positions in Q3 2022 and 5 closed out, a net change of +2 holders.
  • The largest Outlook Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $188K added.
  • The largest Outlook Therapeutics seller in Q3 2022 was Vista Finance, an estimated $724K sold.

Based on aggregated 13F filings for Q3 2022.